Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lusutrombopag

FDA-approved product (tablet, oral), marketed as Mulpleta.

Registered studies
8
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Lusutrombopag
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage
  • Thrombocytopenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other systemic hemostatics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

8registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lusutrombopag in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lusutrombopag with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

    NCT07483385 · start 2026-01-13

    Registered record
    Registry ID
    NCT07483385
    Conditions
    Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation; Hematologic Disorders
    Interventions
    Lusutrombopag
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-01-13
    Completion
    2028-01-28
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation; Hematologic Disorders
    InterventionLusutrombopag
    PhaseNot applicable
    Registry statusRecruiting

  • Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

    NCT06673498 · start 2024-11-10

    Registered record
    Registry ID
    NCT06673498
    Conditions
    Thrombocytopenia
    Interventions
    Lusutrombopag combined with recombinant human thrombopoietin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-10
    Completion
    2025-11-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia
    InterventionLusutrombopag combined with recombinant human thrombopoietin
    PhasePhase 2
    Registry statusRecruiting

  • A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag

    NCT06426043 · start 2024-06

    Registered record
    Registry ID
    NCT06426043
    Conditions
    Aplastic Anemia
    Interventions
    Lusutrombopag
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-06
    Completion
    2025-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAplastic Anemia
    InterventionLusutrombopag
    PhasePhase 4
    Registry statusUnknown

  • Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

    NCT06287567 · start 2024-04-17

    Registered record
    Registry ID
    NCT06287567
    Conditions
    Idiopathic Thrombocytopenic Purpura; Immune Thrombocytopenia
    Interventions
    Lusutrombopag Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-04-17
    Completion
    2025-03-06
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Thrombocytopenic Purpura; Immune Thrombocytopenia
    InterventionLusutrombopag Oral Tablet
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure

    NCT04915287 · start 2021-06-06

    Registered record
    Registry ID
    NCT04915287
    Conditions
    Thrombocytopenia; Drugs; Chronic Liver Disease
    Interventions
    Avatrombopag maleate; Platelet transfusion; Medicine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06-06
    Completion
    2023-07-31
    Enrolment
    476

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia; Drugs; Chronic Liver Disease
    InterventionAvatrombopag maleate; Platelet transfusion; Medicine
    PhasePhase 4
    Registry statusUnknown

  • Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

    NCT02389621 · start 2015-06-15

    Registered record
    Registry ID
    NCT02389621
    Conditions
    Chronic Liver Disease; Thrombocytopenia
    Interventions
    Lusutrombopag; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06-15
    Completion
    2017-04-19
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Liver Disease; Thrombocytopenia
    InterventionLusutrombopag; Placebo
    PhasePhase 3
    Registry statusCompleted

  • An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

    NCT01129024 · start 2010-04-29

    Registered record
    Registry ID
    NCT01129024
    Conditions
    Immune Thrombocytopenia
    Interventions
    Lusutrombopag
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-04-29
    Completion
    2011-06-30
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenia
    InterventionLusutrombopag
    PhasePhase 2
    Registry statusTerminated

  • A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

    NCT01054443 · start 2010-03-18

    Registered record
    Registry ID
    NCT01054443
    Conditions
    Immune Thrombocytopenia (ITP)
    Interventions
    Placebo; Lusutrombopag
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-03-18
    Completion
    2010-11-24
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenia (ITP)
    InterventionPlacebo; Lusutrombopag
    PhasePhase 2
    Registry statusTerminated